Upfront tandem autologous non-myeloablative allogeneic stem cell transplant in high-risk multiple myeloma: a long-term single-centre experience

被引：1
|
作者：
Nguyen, Phillip C. [1 ]
Muirhead, Jenny [1 ]
Tan, Joanne [1 ]
Kalff, Anna [1 ,2 ]
Bergin, Krystal [1 ,2 ]
Walker, Patricia [1 ]
Spencer, Andrew [1 ,2 ]
机构：
[1] Monash Univ, Alfred Hlth, Dept Clin Haematol, Melbourne, Vic, Australia
[2] Monash Univ, Australian Ctr Blood Dis, Melbourne, Vic, Australia
来源：
INTERNAL MEDICINE JOURNAL | 2022年 / 52卷 / 07期
关键词：
multiple myeloma; transplant; high risk; allogeneic; CYTOGENETICS; CONSENSUS; IFM99-03; STANDARD; OUTCOMES;
D O I：
10.1111/imj.15842
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The role of upfront non-myeloablative allogeneic stem cell transplantation (NMA alloSCT) in high-risk multiple myeloma (HR-MM) is unclear. We evaluated outcomes of NMA alloSCT following autologous stem cell transplant (ASCT) compared with ASCT alone for newly diagnosed HR-MM. Two-year progression-free survival was improved in the ASCT-NMA alloSCT group (44% vs 16%; P = 0.035), with a trend for improved overall survival (P = 0.118). These results suggest that ASCT-NMA alloSCT can be considered as upfront therapy in HR-MM.
引用
收藏
页码：1263 / 1267
页数：5
相关论文
共 50 条
  • [21] Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma
    Kuruvilla, John
    Shepherd, Yohn D.
    Sutherland, Heather J.
    Nevill, Thomas J.
    Nitta, Janet
    Le, Aulan
    Forrest, Donna L.
    Hogge, Donna E.
    Lavoie, Julye C.
    Nantel, Stephen H.
    Toze, Cynthia L.
    Smith, Clayton A.
    Barnett, Micheal J.
    Song, Kevin W.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2007, 13 (08) : 925 - 931
  • [22] Outcomes of Tandem Hematopoietic Stem Cell Autologous Transplant in High-Risk Myeloma Patients: A Single-Center Experience
    Philip, Shona
    Lam, Selay
    Phua, Chai Wye
    Louzada, Martha L.
    Xenocostas, Anargyros
    Deotare, Uday
    BLOOD, 2021, 138
  • [23] Autologous hematopoietic stem cell transplantion (HSCT) followed by allograft with non-myeloablative conditioning (tandem protocol) in multiple myeloma patients: A single center experience
    Carella, A. M.
    Greco, M. M.
    Savino, L.
    Bodenizza, C.
    DellOlio, M.
    Falcone, A.
    La Sala, A.
    Mantuano, S.
    Melillo, L.
    Merla, E.
    Nobile, M.
    Sanpaolo, G.
    Scalzulli, F.
    Cascavilla, N.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 105 - 106
  • [24] Is there a curative potential of autologous stem cell transplantation in multiple myeloma? Long-term results from a single-centre series
    Rovira, M.
    Rosinol, L.
    Fernandez-Aviles, F.
    Martinez, C.
    Gine, E.
    Esteve, J.
    Cibeira, M. T.
    Marin, P.
    Carreras, E.
    Blade, J.
    BONE MARROW TRANSPLANTATION, 2009, 43 : S147 - S147
  • [25] Allogeneic stem cell transplantation in multiple myeloma: Single-centre experience of 106 patients
    Uotinen, H.
    Volin, L.
    Juvonen, E.
    Nihtinen, A.
    Ruutu, T.
    BONE MARROW TRANSPLANTATION, 2007, 39 : S153 - S153
  • [26] Long-term outcomes of allogeneic stem cell transplant in multiple myeloma
    Schmidt, Walker M.
    Perera, Nirosha D.
    Buadi, Francis K.
    Hayman, Suzanne R.
    Kumar, Shaji K.
    Dispenzieri, Angela
    Dingli, David
    Cook, Joselle
    Lacy, Martha Q.
    Kapoor, Prashant
    Leung, Nelson
    Muchtar, Eli
    Warsame, Rahma M.
    Kourelis, Taxiarchis
    Binder, Moritz
    Gonsalves, Wilson I.
    Hogan, William J.
    Gertz, Morie A.
    BLOOD CANCER JOURNAL, 2023, 13 (01)
  • [27] Long-term outcomes of allogeneic stem cell transplant in multiple myeloma
    Walker M. Schmidt
    Nirosha D. Perera
    Francis K. Buadi
    Suzanne R. Hayman
    Shaji K. Kumar
    Angela Dispenzieri
    David Dingli
    Joselle Cook
    Martha Q. Lacy
    Prashant Kapoor
    Nelson Leung
    Eli Muchtar
    Rahma M. Warsame
    Taxiarchis Kourelis
    Moritz Binder
    Wilson I. Gonsalves
    William J. Hogan
    Morie A. Gertz
    Blood Cancer Journal, 13
  • [28] UPFRONT TANDEM AUTOLOGOUS STEM CELL TRANSPLANT IS SUPERIOR THAN AUTOLOGOUS OR ALLOGENEIC STEM CELL TRANSPLANT AFTER FAILURE OF 1ST AUTOLOGOUS TRANSPLANT IN PATIENTS WITH MULTIPLE MYELOMA
    Bachier, C.
    Wong, A.
    Shaughnessy, P.
    LeMaistre, C. F.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2012, 18 (02) : S295 - S295
  • [29] Tandem autologous non-myeloablative allogeneic transplantation in patients with multiple myeloma relapsing after a first high dose therapy
    L Karlin
    B Arnulf
    S Chevret
    L Ades
    M Robin
    R P De Latour
    M Malphettes
    N Kabbara
    B Asli
    V Rocha
    J P Fermand
    G Socie
    Bone Marrow Transplantation, 2011, 46 : 250 - 256
  • [30] NON MYELOABLATIVE ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS WITH HIGH RISK LYMPHOMA: A SINGLE CENTRE EXPERIENCE
    Console, G.
    Messina, G.
    Martino, M.
    Irrera, G.
    Pucci, G.
    Moscato, T.
    Fedele, R.
    Massara, E.
    Cuzzola, M.
    Gatto, F.
    Spiniello, E.
    Meliado, A.
    Rigolino, C.
    Dattola, A.
    Gareffa, C.
    Callea, I
    Pontari, A.
    Monteleone, R.
    Stelitano, C.
    Callea, V
    Mamone, D.
    Kropp, M. G.
    Molica, S.
    Vigliotti, M. L.
    Iacopino, P.
    HAEMATOLOGICA, 2008, 93 : S102 - S102
12345